Drugs / VX-973
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06615570 | Sep 2024 → Jul 2025 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05866055 | May 2023 → Apr 2024 | — | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VX-973 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06615570 ↗ |
| Route | Oral | “Suspension for oral administration.” NCT05866055 ↗ |